Head and Neck Cancer
Conditions
Brief summary
The purpose of this study is to determine whether Ultrasound Hyperthermia is effective and safe in the treatment of Oral and Maxillofacial-Head and Neck Cancer.
Detailed description
As a non-invasive treatment, Ultrasound Hyperthermia has received increasing interest for the treatment of cancer.Many studies have shown that Therapeutic Ultrasound is safe and effective. Eligible patients were randomly assigned by using permutated blocks designed for each site to receive either Ultrasound Hyperthermia combined with chemotherapy (Arm A) or chemotherapy alone(Arm B).Chemotherapy will be conducted as follows. For Squamous cell carcinoma of head and neck,it will be administrated with Docetaxel(at a dose of 75 mg per square meter of body-surface area and intravenous infused in 1 hr at day 1rt), Cisplatin(at a dose of 75 mg per square meter of body-surface area and intravenous infused in 1 hr at day 1rt) and Fluorouracil(at a dose of 75 mg per square meter of body-surface area and intravenous infused last 5 days) . For other types of cancer,the treatments will be administrated in accord with the guideline.In addition,Ultrasound Hyperthermia will be conducted 5 times(day 1rt,3rd,5th,7th,9th) in Arm A. Patients in arm B will receive chemotherapy only. One cycle comprises a period of 3 weeks (21 days).All patients will receive 2 cycles in both arms. All the patients eligible for the operation will take surgery. After treatment，some patients with advanced unresectable cancer may be down-staged from stage IV, and will regain the opportunity of operation.
Interventions
DEVICEUltrasound Hyperthermia
treated with Therapeutic Ultrasound device on the 1st,3rd,5th,7th,9th day of each 21 day cycle
Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)
Sponsors
Xuzhou Central Hospital
Wei Guo
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Joined the study voluntary and signed informed consent form * Age 18-75，both genders. * Had histologically or cytologically confirmed advanced squamous cell carcinoma of the head and neck * At least one lesions can be measured,Conventional measurements ≥2cm, computed tomography(CT) examination ≥1cm . * Eastern Cooperative Oncology Group(ECOG) Performance Scale 0-2. * Life expectancy of more than 6 months. * Use of an effective contraceptive method for women when there is a risk of pregnancy during the study. * Haemoglobin≥90g/L ,White blood cell(WBC) ≥3×10\^9/L * Hepatic function:ALAT、ASAT\< 2.5 x ULN, TBIL\< 1.5 x ULN * Renal function: Creatinine \< 1.5 x ULN
Exclusion criteria
* Participation in other interventional clinical trials within 1 month * Previous received other drug or operative treatment within 6 month * Pregnant or breast-feeding women * History of serious allergic or allergy * Patients with the history of Serious lung or head disease * Local skin ulceration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of Disease Control | one year |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival | three years |
| Over Survival | three years |
Countries
China
Contacts
Primary ContactWei Guo, PhD
Outcome results
None listed